Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsFRA:HTD -1.99%85 Cash-to-Debt is 32.72 as of Jun. 2026, which is 81% below its 10-year median of 168.11. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €60.80 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,393 Biotechnology companies, Corcept Therapeutics ranks better than 67.48% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Corcept Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 32.72.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Corcept Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Corcept Therapeutics's Cash-to-Debt or its related term are showing as below:
FRA:HTD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.56 Med: 168.11 Max: No Debt
Current: 32.71
During the past 13 years, Corcept Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.56. And the median was 168.11.
FRA:HTD's Cash-to-Debt is ranked better than 67.48% of 1393
companies
in the Biotechnology industry
Industry Median: 6.72
vs FRA:HTD: 32.71
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Corcept Therapeutics Cash-to-Debt Related Terms
Corcept Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:HTD vs APGE, KRYS, NUVL: Cash-to-Debt Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (FRA:HTD) has a Cash-to-Debt of 32.72 as of Jun. 2026. This is 81% below median its historical median of 168.11. Over the past decade, Corcept Therapeutics' Cash-to-Debt has ranged from 2.56 to 10,000.00. According to the industry distribution chart, Corcept Therapeutics ranks #453 out of 1393 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Corcept Therapeutics' Cash-to-Debt too high?
Corcept Therapeutics' current Cash-to-Debt of 32.72 is 81% below median its 10-year median of 168.11. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Corcept Therapeutics' value of 32.72 is 386.9% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #453 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Cash-to-Debt compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #453 out of 1393 companies for Cash-to-Debt. This puts Corcept Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.72. Corcept Therapeutics' value of 32.72 is 386.9% above this benchmark. Historically, Corcept Therapeutics' own Cash-to-Debt has ranged from 2.56 to 10,000.00 over the past decade. While the company's 10-year median is 168.11 vs. the industry median of 6.72, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Cash-to-Debt of 32.72 is 386.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Cash-to-Debt is 32.72, which is 81% below median its own 10-year median of 168.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €60.80, compared to a current price of €98.16 — trading 61.4% above its estimated fair value. The current Cash-to-Debt is 32.72, which is 81% below median its 10-year median of 168.11 and 386.9% above the Biotechnology industry median of 6.72. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Cash-to-Debt is 32.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €98.16 is trading 61.4% above its estimated GF Value™ of €60.80.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
Cash-to-Debt: 32.72 (81% below median its 10-year median of 168.11)
GF Value™: €60.80 vs. price of €98.16 (61.4% above fair value)
Industry Position: 386.9% above the Biotechnology median (#453 of 1393)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
